BRN.AX BrainChip (ASX) A$0.155 pre-market 03 Feb 2026: earnings on 04 Mar

BRN.AX stock is trading at A$0.155 pre-market on 03 Feb 2026 with 10,813,680 shares changing hands yesterday. We see the imminent earnings announcement on 04 Mar 2026 as the main near-term catalyst for BrainChip Holdings Ltd (BRN.AX) on the ASX. Volume is elevated versus the 50-day average, and the company’s Akida neuromorphic chips keep BrainChip in the AI stocks conversation. Meyka AI provides this data-driven market view to frame risks and upside ahead of the report.

BRN.AX stock performance and market snapshot

BrainChip Holdings Ltd (BRN.AX) opened at A$0.145 and is quoted at A$0.155 pre-market. The stock’s day range is A$0.145–0.155, year range A$0.145–0.34, market cap A$341.98M, and volume 10,813,680 versus avg vol 8,473,980. Price averages show the 50-day at A$0.17 and the 200-day at A$0.20, signalling recent downward pressure.

Financials, growth and BRN.AX stock valuation

Key metrics show EPS -0.02 and PE -7.25, reflecting loss-making status. Trailing metrics include price-to-sales 181.12 and price-to-book 13.79, while current ratio is 5.18 and cash per share A$0.00647. FY2024 revenue grew 71.55%, but operating margins remain negative at -17.03%, so growth is real but cash burn and valuation multiples stay elevated.

Technicals and short-term indicators for BRN.AX stock

Momentum indicators read RSI 60.30, CCI 137.05 and Stochastic %K 90.48, suggesting short-term strength and possible overbought conditions. Bollinger Bands sit 0.15–0.19, ATR 0.01, and on-balance volume remains negative. Traders should watch the A$0.15 support and A$0.17–0.19 resistance area for near-term price action.

Meyka AI grade, forecast and price targets for BRN.AX stock

Meyka AI rates BRN.AX with a score of 64.90 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of A$0.1904. Compared with the current A$0.155, that implies an upside of 22.83%. Forecasts are model-based projections and not guarantees.

Risks, sector context and BRN.AX stock outlook

BrainChip sits in the Technology sector and Semiconductors industry where average P/E is higher and growth expectations are steep. External risk includes continued losses, thin institutional coverage, and high valuation multiples. Company rating data shows a third-party score of C- (Strong Sell) on 30 Jan 2026, highlighting divergent views between models and some analysts.

Catalysts and trading strategy for BRN.AX stock

Primary catalysts are the earnings release on 04 Mar 2026, product adoption updates for the Akida platform, and any OEM partnerships. For AI stocks traders, consider a staged approach: accumulation under A$0.15, partial profit-taking near A$0.19–0.21, and stop-loss sizing to limit downside. Liquidity is adequate with avg vol 8.47M, but volatility remains high.

Final Thoughts

Key takeaways for BRN.AX stock: BrainChip trades at A$0.155 pre-market on 03 Feb 2026 with elevated volume and upcoming earnings on 04 Mar 2026 as the primary catalyst. Financials show fast revenue growth (FY2024 +71.55%) but persistent operating losses and stretched valuation metrics — price-to-sales 181.12 and price-to-book 13.79. Meyka AI’s forecast model projects a yearly price of A$0.1904, implying a 22.83% upside versus the current price; conservative and optimistic near-term price targets are A$0.11 and A$0.21 respectively. Our Meyka grade is B / HOLD, reflecting balanced upside potential against execution and cash-flow risk. Investors focused on AI edge chips should weigh product milestones and the March earnings print, and treat model outputs as probabilistic, not guaranteed outcomes. Meyka AI is the AI-powered market analysis platform used to generate these projections.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.